<HTML>

<HEAD>

<TITLE>A Breast-Cancer Protocol</TITLE>

<META NAME="GENERATOR" CONTENT="Internet Assistant for Word 2.0z Beta">
</HEAD>

<BODY>
<center><H1>A Breast-Cancer Protocol </H1></center>
<i>from Eastern Cooperative Oncology Group, Protocol EST 2190, PDQ version </i>
<hr>
<a href="breast-cancer.gif"><b>Accompanying schematic protocol flowchart</a></b><p>

The following is a PDQ version that contains code for the content (e.g., OBJ for the objective of the protocol).
<p>
<pre>
NR  	      	PROTOCOL
NAME	001001	NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Study of Adjuvant CAF
NAME	001002	(CTX/DOX/5-FU) vs Adjuvant CAF Followed by Intensification with High-Dose
NAME	001003	CTX/TSPA plus Autologous Stem Cell Rescue in Women with Stage II/III Breast
NAME	001004	Cancer at High Risk of Recurrence (Summary Last Modified 12/94)
UI  	001001	199/08422
ID  	001001	EST-2190
ID  	002001	INT-0121
TYPE	001001	treatment clinical trial
STAT	001001	Active
SDAT	001001	08/07/91
AGET	001001	15 to 60
AGEL	001001	15
AGEH	001001	60
PHAS	001001	phase III study
PHUI	001001	208/01136
CENT	001001	breast cancer
CENT	002001	stage II breast cancer
CENT	003001	stage III breast cancer
CENT	004001	stage IIIA breast cancer
CENT	005001	cancer
CENT	006001	stage IIIB breast cancer
CENT	007001	body system/site cancer
CENT	008001	adult solid tumor
CENT	009001	solid tumor
CENT	010001	stage, breast cancer
CENT	011001	cancer-related problem/condition
CENT	012001	bone marrow suppression
CENT	013001	bone marrow ablation
CEUI	001001	208/00013
CEUI	002001	208/00015
CEUI	003001	208/00016
CEUI	004001	208/00018
CEUI	005001	208/00041
CEUI	006001	208/00052
CEUI	007001	208/00903
CEUI	008001	208/03335
CEUI	009001	208/03336
CEUI	010001	208/03501
CEUI	011001	208/04452
CEUI	012001	208/04478
CEUI	013001	208/04933
PSCE	001001	bone marrow ablation
PSCE	002001	stage II breast cancer
PSCE	003001	stage IIIA breast cancer
PSCE	004001	stage IIIB breast cancer
PSUI	001001	208/04933
PSUI	002001	208/00015
PSUI	003001	208/00018
PSUI	004001	208/00052
TMOD	001001	chemotherapy
TMOD	002001	biological response modifier therapy
TMOD	003001	radiation therapy
TMOD	004001	low-LET photon therapy
TMOD	005001	hormone therapy
TMOD	006001	autologous bone marrow transplantation
TMOD	007001	low-LET electron therapy
TMOD	008001	endocrine therapy
TMOD	009001	antiestrogen therapy
TMOD	010001	bone marrow transplantation
TMOD	011001	colony stimulating factor therapy
TMOD	012001	peripheral blood stem cell transplantation
TMOD	013001	cytokine therapy
TMOD	014001	bone marrow ablation with stem cell support
TMUI	001001	208/00209
TMUI	002001	208/00381
TMUI	003001	208/01063
TMUI	004001	208/01131
TMUI	005001	208/01139
TMUI	006001	208/01141
TMUI	007001	208/01550
TMUI	008001	208/01562
TMUI	009001	208/01571
TMUI	010001	208/02453
TMUI	011001	208/03629
TMUI	012001	208/04247
TMUI	013001	208/04710
TMUI	014001	208/05304
DRUG	001001	cyclophosphamide
DRUG	002001	cyclophosphamide/doxorubicin/fluorouracil
DRUG	003001	cyclophosphamide/thiotepa
DRUG	004001	doxorubicin
DRUG	005001	doxorubicin/fluorouracil/thiotepa
DRUG	006001	fluorouracil
DRUG	007001	granulocyte-macrophage colony stimulating factor
DRUG	008001	tamoxifen
DRUG	009001	thiotepa
DRUI	001001	208/00241
DRUI	002001	208/04011
DRUI	003001	208/00053
DRUI	004001	208/00135
DRUI	005001	208/04116
DRUI	006001	208/00757
DRUI	007001	208/03465
DRUI	008001	208/00673
DRUI	009001	208/00680
OBJ 	001001	OBJECTIVES:
OBJ 	001002	I.  Compare sites and rates of recurrence, disease-free survival, overall
OBJ 	001003	survival, and toxicity of adjuvant chemotherapy with CAF (cyclophosphamide,
OBJ 	001004	doxorubicin, fluorouracil) vs. adjuvant CAF followed by marrow ablation with
OBJ 	001005	cyclophosphamide/thiotepa and autologous stem cell rescue in women with Stage
OBJ 	001006	II/III breast cancer and 10 or more positive lymph nodes.
OBJ 	001007	
OBJ 	001008	II.  Evaluate prospectively the incidence and degree of occult marrow
OBJ 	001009	contamination with breast cancer cells at the time of study entry and
OBJ 	001010	following CAF chemotherapy by analyzing samples of marrow using a panel of
OBJ 	001011	monoclonal antibodies specific for breast cancer.
OBJ 	001012	
OBJ 	001013	III.  Document the changes in psychosocial function that occur during
OBJ 	001014	treatment on either regimen, and compare post-treatment recovery of
OBJ 	001015	psychosocial function.
OBJ 	001016	
OBJ 	001017	IV.  Establish a bank of paraffin-embedded tumor samples for future laboratory
OBJ 	001018	study.
CRIT	001001	PROTOCOL ENTRY CRITERIA:
CRIT	001002	
CRIT	001003	--Disease Characteristics--
CRIT	001004	
CRIT	001005	Biopsy-proven epithelial carcinoma of the breast with at
CRIT	001006	least 10 involved lymph nodes
CRIT	001007	
CRIT	001008	Stage II/III disease
CRIT	001009	  Synchronous bilateral breast cancer eligible provided
CRIT	001010	  primaries occurred within 6 weeks of each other
CRIT	001011	
CRIT	001012	  Contralateral intraductal cancer eligible
CRIT	001013	
CRIT	001014	The following conditions exclude:
CRIT	001015	  T4 or N2 disease
CRIT	001016	  Apocrine, adenoidcystic, or squamous carcinoma
CRIT	001017	  Inflammatory carcinoma of the breast
CRIT	001018	  Lesions fixed to skin or chest wall
CRIT	001019	  Peau d'orange skin changes
CRIT	001020	  Matted axillary nodes
CRIT	001021	  Asynchronous bilateral infiltrating breast cancer
CRIT	001022	
CRIT	001023	Radical or modified radical mastectomy or breast-sparing
CRIT	001024	surgery with axillary dissection required within 12 weeks of
CRIT	001025	entry
CRIT	001026	
CRIT	001027	  Negative surgical margins required
CRIT	001028	
CRIT	001029	  Type of procedure, number of nodes examined, number of
CRIT	001030	  positive nodes, and tumor size must be reported
CRIT	001031	
CRIT	001032	  Breast-sparing surgery must have included wide excision
CRIT	001033	  (i.e., removal of gross tumor plus normal breast tissue)
CRIT	001034	
CRIT	001035	Bone marrow aspirate, bilateral core biopsy, and bone scan
CRIT	001036	must be negative for tumor
CRIT	001037	  Aspiration and biopsy not required for patients who received
CRIT	001038	  1 course of cyclophosphamide/doxorubicin/fluorouracil (CAF)
CRIT	001039	  prior to entry
CRIT	001040	
CRIT	001041	Hormone receptor status:
CRIT	001042	  Estrogen and progesterone receptor status must be determined
CRIT	001043	  by either biochemical or immunohistochemical assays
CRIT	001044	
CRIT	001045	--Prior/Concurrent Therapy--
CRIT	001046	
CRIT	001047	Biologic therapy:
CRIT	001048	  No prior therapy with colony stimulating factors for breast
CRIT	001049	  cancer
CRIT	001050	
CRIT	001051	Chemotherapy:
CRIT	001052	  1 prior cycle of CAF allowed provided documentation of
CRIT	001053	  treatment is available
CRIT	001054	
CRIT	001055	Endocrine therapy:
CRIT	001056	  No prior hormonal therapy for breast cancer except up to 21
CRIT	001057	  days of tamoxifen that is stopped prior to entry
CRIT	001058	
CRIT	001059	  Prior postmenopausal estrogen therapy allowed but must be
CRIT	001060	  discontinued prior to entry
CRIT	001061	
CRIT	001062	Radiotherapy:
CRIT	001063	  No prior radiotherapy
CRIT	001064	  Postoperative radiotherapy required on study
CRIT	001065	
CRIT	001066	Surgery:
CRIT	001067	  Surgery completed no more than 12 weeks prior to entry
CRIT	001068	
CRIT	001069	--Patient Characteristics--
CRIT	001070	
CRIT	001071	Age:
CRIT	001072	  15 to 60
CRIT	001073	
CRIT	001074	Sex:
CRIT	001075	  Female only
CRIT	001076	
CRIT	001077	Menopausal status:
CRIT	001078	  Pre- or postmenopausal
CRIT	001079	
CRIT	001080	Performance status:
CRIT	001081	  ECOG 0 or 1
CRIT	001082	
CRIT	001083	Hematopoietic:
CRIT	001084	  (obtained within 2 weeks prior to entry)
CRIT	001085	  WBC at least 4,000
CRIT	001086	  Platelets at least 100,000
CRIT	001087	
CRIT	001088	Hepatic:
CRIT	001089	  (obtained within 2 weeks prior to entry)
CRIT	001090	  Bilirubin no more than 1.2 x normal
CRIT	001091	  SGOT (or SGPT) no more than 1.2 x normal
CRIT	001092	  Alkaline phosphatase no more than 1.2 x normal
CRIT	001093	
CRIT	001094	Renal:
CRIT	001095	  Not specified
CRIT	001096	
CRIT	001097	Cardiovascular:
CRIT	001098	  LVEF (by MUGA) at least 50% or equal to or greater than the
CRIT	001099	     lower limit of institutional normal
CRIT	001100	  No prior angina pectoris requiring nitrate therapy
CRIT	001101	  No MI within 6 months
CRIT	001102	  No uncontrolled CHF
CRIT	001103	  No uncontrolled hypertension
CRIT	001104	  No major ventricular arrhythmia
CRIT	001105	
CRIT	001106	Pulmonary:
CRIT	001107	  FEV1 at least 60% of predicted
CRIT	001108	  DLCO (corrected) at least 60% of predicted
CRIT	001109	  Lung volume at least 60%
CRIT	001110	  No symptomatic obstructive or restrictive lung disease
CRIT	001111	
CRIT	001112	Other:
CRIT	001113	  No symptomatic CNS disease of any etiology
CRIT	001114	  No insulin-dependent diabetes mellitus
CRIT	001115	  No uncompensated major thyroid dysfunction
CRIT	001116	  No uncompensated major adrenal dysfunction
CRIT	001117	  No HIV positivity
CRIT	001118	  No prior malignancy within 5 years except:
CRIT	001119	     In situ breast cancer (lobular or ductal)
CRIT	001120	     Inactive nonmelanomatous skin cancer
CRIT	001121	     In situ cervical cancer
CRIT	001122	  No pregnant or nursing women
CRIT	001123	  Assessment of insurance coverage required
CRIT	001124	
WARN	001001	WARNING:
WARN	001002	Many protocols are potentially hazardous, are intended only for use by
WARN	001003	clinical oncologists in carefully structured settings, and may not prove to be
WARN	001004	more effective than standard treatment.  A responsible investigator associated
WARN	001005	with this protocol should be consulted before using this protocol.  Dose and
WARN	001006	schedule modifications are required for patients who develop gastrointestinal,
WARN	001007	hematologic, neurologic, and biochemical (renal, hepatic, etc.) and/or other
WARN	001008	abnormalities after the administration of therapy.  Additionally, Federal
WARN	001009	regulations for the protection of human subjects require approval of clinical
WARN	001010	trials by your local Institutional Review Board.
OUTL	001001	PROTOCOL OUTLINE:
OUTL	001002	Randomized study.  Patients are randomized 50:50 to conventional adjuvant
OUTL	001003	therapy on Arm I vs. conventional adjuvant therapy followed by marrow
OUTL	001004	ablation/rescue on Arm II.  Patients unable to undergo marrow ablation/rescue
OUTL	001005	for whatever reason will not be crossed to Arm I but will be followed.  All
OUTL	001006	patients receive postoperative radiotherapy on Regimen A following completion
OUTL	001007	of chemotherapy.  Patients with ER-positive or PgR-positive tumor receive
OUTL	001008	antiestrogen therapy with tamoxifen on Regimen B.
OUTL	001009	
OUTL	001010	The following acronyms are used:
OUTL	001011	  ABM      Autologous Bone Marrow
OUTL	001012	  CTX      Cyclophosphamide, NSC-26271
OUTL	001013	  DOX      Doxorubicin, NSC-123127
OUTL	001014	  5-FU     Fluorouracil, NSC-19893
OUTL	001015	  G-CSF    Granulocyte Colony Stimulating Factor (Amgen)
OUTL	001016	           NSC-614629
OUTL	001017	  GM-CSF   Granulocyte-Macrophage Colony Stimulating Factor
OUTL	001018	           (any commercially available brand)
OUTL	001019	  PBSC     Peripheral Blood Stem Cells
OUTL	001020	  TMX      Tamoxifen, NSC-180973
OUTL	001021	  TSPA     Thiotepa, NSC-6396
OUTL	001022	
OUTL	001023	Arm I:  3-Drug Combination Chemotherapy.  CAF:  CTX/DOX/5-FU.
OUTL	001024	
OUTL	001025	Arm II:  3-Drug Combination Chemotherapy followed by 2-Drug Marrow Ablation
OUTL	001026	followed by Autologous Stem Cell Rescue and Growth Factor Therapy.  CAF;
OUTL	001027	followed by CTX/TSPA; followed by ABM or PBSC; and GM-CSF (or G-CSF, at the
OUTL	001028	investigator's discretion).
OUTL	001029	
OUTL	001030	Regimen A:  Radiotherapy.  Irradiation of remaining breast tissue (lumpectomy
OUTL	001031	patients) or chest wall (mastectomy patients) plus regional lymphatics using
OUTL	001032	megavoltage equipment with peak photon energies of no more than 6 MV (greater
OUTL	001033	energy may be required in large-breasted women) and electron boosts with
OUTL	001034	energies of 6-9 MeV as appropriate.
OUTL	001035	
OUTL	001036	Regimen B:  Antiestrogen Therapy.  TMX.
STRT	001001	STRATIFICATION BY:
STRT	001002	Participating institution, ER status (negative vs. positive), age (39 and
STRT	001003	under vs. 40 and over), menopausal status (pre- vs. postmenopausal).
PARM	001001	SPECIAL STUDY PARAMETERS:
PARM	001002	Hemogram (including reticulocytes), liver and kidney function tests, bone
PARM	001003	marrow aspirate and biopsy, chest x-ray, pulmonary function tests, LVEF, EKG,
PARM	001004	bone scan, mammogram, Breast Chemotherapy Questionnaire, pelvic exam.  In
PARM	001005	transplant patients only:  dental consult, arterial blood gases, viral titers
PARM	001006	(Herpes simplex, CMV, Varicella, HIV), HBsAg.  As indicated:  creatinine
PARM	001007	clearance, liver scan, brain scan.  Recommended:  pregnancy test.
ENDP	001001	END POINTS:
ENDP	001002	Incidence of recurrence, site of recurrence, disease-free survival, overall
ENDP	001003	survival, toxicity/morbidity of treatment, effect of therapy on psychosocial
ENDP	001004	function, rate of occult marrow contamination.
PROJ	001001	PROJECTED ACCRUAL:
PROJ	001002	429 patients will be accrued over an estimated 3 years.
DOSE	001001	DOSAGE SCHEDULE:
DOSE	001002	Treatment must start within 72 hours of randomization; CAF chemotherapy doses
DOSE	001003	are based on actual weight.  In patients in whom actual and ideal weights are
DOSE	001004	not the same, CTX/TSPA doses are based on corrected ideal weight (ideal plus
DOSE	001005	25% of the difference of actual less ideal).  Cytokine doses are based on the
DOSE	001006	lesser of ideal or actual weight.
DOSE	001007	
DOSE	001008	Arm I:  CAF:  CTX - 100 mg/sqm (rounded to the nearest 25 mg) po on days 1
DOSE	001009	through 14; DOX - 30 mg/sqm iv on days 1 and 8; 5-FU - 500 mg/sqm iv on days 1
DOSE	001010	and 8.  Doses of CTX are administered as a single daily dose, if possible, and
DOSE	001011	doses of 75 or 175 mg will be administered as alternating doses of 50 and 100
DOSE	001012	mg or 150 and 200 mg, respectively.  Courses repeat q 4 weeks for a total of 6
DOSE	001013	courses (1 course may have been received prior to entry).  The doses of all 3
DOSE	001014	agents are increased 20% if nadir granulocytes and platelets were greater than
DOSE	001015	2,000 and 100,000, respectively, on the previous course.  Stem cell harvest is
DOSE	001016	strongly recommended for use at relapse; further therapy will be off protocol.
DOSE	001017	
DOSE	001018	Stem cell harvests:  Bone marrow harvest is instituted no sooner than 4 weeks
DOSE	001019	and no later than 8 weeks following the last dose of CAF, provided the
DOSE	001020	following criteria are met:  neutrophils at least 1,200, platelets at least
DOSE	001021	100,000, and bone marrow normocellular (at least 25%) and free of tumor by
DOSE	001022	bilateral iliac crest biopsy within 4 weeks of storage.  A minimum harvest of
DOSE	001023	10 to the eighth nucleated cells/kg of body weight is required.  Additionally,
DOSE	001024	PBSC (at least 7 x 10 to the ninth mononuclear cells/kg with at least 5 x 10
DOSE	001025	to the fourth CFU-GM/kg) should be harvested.  Cytokine (but not chemotherapy)
DOSE	001026	priming is permitted.
DOSE	001027	
DOSE	001028	Arm II:  CAF:  CTX, DOX, and 5-FU as in Arm I.  High-dose chemotherapy and
DOSE	001029	rescue is initiated following stem cell harvests (see above) provided patients
DOSE	001030	meet the following eligibility requirements:  no evident breast cancer;
DOSE	001031	adequate bone marrow harvested; ECOG performance status 0 or 1; absence of all
DOSE	001032	infection off antibiotics; serum creatinine no greater than 2.0 md/dl;
DOSE	001033	alkaline phosphatase and SGOT no greater than 1.2 x normal and serum direct
DOSE	001034	bilirubin less than 2.0 mg/dl; LVEF at least 50% or no less than the lower
DOSE	001035	limit of institutional normal; and FEV1 and DLCO at least 60% of predicted.
DOSE	001036	CTX - 6,000 mg/sqm by continuous iv infusion over 96 hours, beginning on day
DOSE	001037	-6 (1,500 mg/sqm/day in 250-500 ml D5W); TSPA - 800 mg/sqm by continuous iv
DOSE	001038	infusion over 96 hours via a separate line, beginning on day -6 (200
DOSE	001039	mg/sqm/day in 500 ml D5W), with continuous bladder irrigation (500 ml NS/hour)
DOSE	001040	beginning with CTX and continuing until 24 hours after CTX; ABM and/or PBSC -
DOSE	001041	at least 10 to the eighth nucleated bone marrow cells/kg and/or at least 10 to
DOSE	001042	the ninth nucleated PBSC thawed and infused as rapidly as possible 48-72 hours
DOSE	001043	after completion of chemotherapy; GM-CSF - 250 mcg/sqm/day (or G-CSF - 5-10
DOSE	001044	mcg/kg/day) is recommended, with the schedule and route of administration at
DOSE	001045	the investigator's discretion.
DOSE	001046	
DOSE	001047	Patients on Arm II receive the following prophylactic therapy:
DOSE	001048	trimethoprim/sulfamethoxazole - 1 double-strength tablet BID from days -7
DOSE	001049	through 90 (schedule may be modified to suit the investigator and
DOSE	001050	institutional practice) with leucovorin - 5 mg po daily; acyclovir - 250
DOSE	001051	mg/sqm iv q 8 hours on days -3 through 17.
DOSE	001052	
DOSE	001053	Regimen A:  Treatment begins within 4 weeks of completing chemotherapy (Arm I)
DOSE	001054	or within 8 weeks following stem cell rescue (Arm II) or upon recovery of WBC
DOSE	001055	and platelets to greater than 2,900 and 100,000, respectively.  Radiotherapy -
DOSE	001056	5,000 cGy in 25 daily fractions of 200 cGy, 5 days/week, over 5 weeks.  In
DOSE	001057	lumpectomy patients, the field includes the entire remaining breast and
DOSE	001058	underlying chest wall with margins of 1.5-2.0 cm.  In mastectomy patients, the
DOSE	001059	field includes the entire chest wall; in patients in whom the surgical
DOSE	001060	incision and/or drain site(s) extend beyond the photon field margins, en face
DOSE	001061	electrons are delivered to a field including the incision and/or drain sites
DOSE	001062	with a 3-cm margin in continuity with the photon fields.  Additionally, the
DOSE	001063	supraclavicular and axillary lymph nodes are treated to 5,000 cGy, but no
DOSE	001064	attempt is made to treat the internal mammary lymph nodes.
DOSE	001065	
DOSE	001066	Regimen B:  Treatment begins 28 days after the start of the last CAF course
DOSE	001067	(Arm I) or following stem cell infusion when the WBC exceeds 4,000 or the ANC
DOSE	001068	exceeds 2,000 (Arm II).  TMX - 20 mg/day (or 10 mg BID) po for 5 years.
DOSE	001069	
DOSE	001070	Patients are taken off study if metastatic disease intervenes (rebiopsy of
DOSE	001071	metastatic disease is strongly encouraged with re-analysis of receptor
DOSE	001072	status); such patients may proceed to bone marrow transplant off study.
DOSE	001073	Patients who experience unacceptable toxicity remain on study and are followed
DOSE	001074	for progression and survival; the rare patient who experiences unacceptable
DOSE	001075	toxicity on CAF proceeds to marrow ablation and rescue if randomized to such
DOSE	001076	therapy.  Development of an intercurrent illness that prevents continuation of
DOSE	001077	therapy or regular follow-up may result in removal from study.  All patients
DOSE	001078	are followed for survival.
DOSE	001079	
DOSE	001080	--Toxicities--
DOSE	001081	Toxicities requiring dosage modification on this protocol include the
DOSE	001082	following (see the protocol document for details):
DOSE	001083	
DOSE	001084	Cardiovascular:
DOSE	001085	  Clinical CHF
DOSE	001086	  Malignant arrhythmia
DOSE	001087	  Decreased LVEF
DOSE	001088	  Other cardiac or pericardial toxicity
DOSE	001089	
DOSE	001090	Dermatologic:
DOSE	001091	  Moist desquamation
DOSE	001092	
DOSE	001093	Gastrointestinal:
DOSE	001094	  Intractable nausea/vomiting
DOSE	001095	  Mucositis
DOSE	001096	  Dysphagia
DOSE	001097	  Odynophagia
DOSE	001098	
DOSE	001099	Hematologic:
DOSE	001100	  Granulocytopenia
DOSE	001101	  Thrombocytopenia
DOSE	001102	
DOSE	001103	Hepatic:
DOSE	001104	  Elevated transaminases
DOSE	001105	  Hyperbilirubinemia
DOSE	001106	
DOSE	001107	Pulmonary:
DOSE	001108	  Grade 2 or worse toxicity
DOSE	001109	
DOSE	001110	Renal/Urologic:
DOSE	001111	  Hemorrhagic cystitis
DOSE	001112	
DOSE	001113	Additional toxicities may occur.  Consult one of the investigators associated
DOSE	001114	with this protocol for information.
FORM	001001	DOSAGE FORMS:
FORM	001002	CTX - 25 and 50 mg tablets and 100, 200, 500, 1,000, and 2,000 mg vials; DOX -
FORM	001003	10, 20, 50, 100, and 150 mg vials; 5-FU - 500 mg ampules and 1, 2.5, and 5 g
FORM	001004	vials; TSPA - 15 mg vials; GM-CSF - 250 and 500 mcg vials; G-CSF - 600 mcg
FORM	001005	vials; TMX - 10 mg tablets.
<pre>
<hr>
Back to <A HREF="http://smi-web.stanford.edu/projects/intermed-web/p">Stanford Intermed Index page</A><ADDRESS>
This file was last updated on 3/6/96 by Samson Tu <A HREF="mailto:tul@smi.stanford.edu">tu@smi.stanford.edu</a>
</ADDRESS>
</BODY>
</HTML>


